July 2024
FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment
FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter
Pfizer Advances Development of Once-Daily Oral GLP-1 Receptor Agonist Danuglipron for Obesity Treatment
Pfizer, Danuglipron, GLP-1 Receptor Agonist, Obesity Treatment, Once-Daily Formulation, Clinical Trials, Weight Loss Medication
Novartis to Wind Down San Diego Technical Research and Development Site by Mid-2025
Novartis, San Diego, Technical Research and Development, Site Closure, Layoffs, Restructuring
Ipsen Licenses Second ADC via $1B Bet on Foreseen Bio Asset
Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Licensing Agreement, $1 Billion Deal
Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment
Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Cancer Treatment, Global Licensing Agreement, FS001
FTC to Sue Major PBMs Over Insulin and Drug Prices Amid Anticompetitive Concerns
FTC, PBMs, Insulin Prices, Drug Prices, Anticompetitive Practices, Pharmacy Benefit Managers, Health Companies, Legal Action
Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology
, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,
Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment
Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis